HomeNewsBusinessPersonal FinanceThe average COVID-19 claim size has started decreasing with time: New India Assurance

The average COVID-19 claim size has started decreasing with time: New India Assurance

We have extended cashless facilities to over 90 per cent of the cases so far

July 23, 2020 / 09:34 IST
Story continues below Advertisement

Central and state governments, the insurance regulator, insurers and hospitals are working towards evolving some standardisation in COVID-19 treatment charges, New India Assurance Chairman and Managing Director Atul Sahai, also the chairman of General Insurance Council, tells Preeti Kulkarni in this exclusive interview.

What was New India’s experience with managing the business in the first quarter of 2020-21?

Story continues below Advertisement

The three months (April-June) have been quite challenging. The industry has seen a decline of 9-10 per cent, though New India has grown by around 6 per cent. We did not see a dip in any of the three months.  So, we are rather happy that we have defied the trend. Barring motor, aviation and marine, we have done well. Now, vehicles are not getting sold, cargo is not moving and aviation is badly hit, so these three segments are especially impacted. On the other hand, personal accident, health, property and miscellaneous are showing growth for us.

What were the challenges New India Assurance encountered while handling COVID-19 claims?

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show